The Plaque Psoriasis market continues to evolve as one of the most significant segments within dermatology and immunology, driven by innovation, increasing disease awareness, and the introduction of targeted therapies. With a growing patient population and expanding treatment landscape, the market is witnessing strong momentum across major regions, including North America, Europe, and Asia-Pacific. Pharmaceutical companies and research organizations are investing heavily in novel biologics, biosimilars, and precision medicine approaches, reshaping treatment paradigms and improving patient outcomes. The increasing burden of chronic autoimmune diseases and advancements in diagnostic capabilities are further propelling the growth of the “Plaque Psoriasis Market Size“ ly.
Plaque Psoriasis Understanding
The Plaque Psoriasis Treatment market is a dynamic and essential segment within the pharmaceutical and healthcare industry. Plaque psoriasis is a chronic autoimmune skin condition characterized by red, itchy, and scaly patches that can significantly impact a patient’s quality of life. The disease is driven by immune system dysfunction, leading to accelerated skin cell production and inflammation.
Over the past decade, understanding of the pathophysiology of plaque psoriasis has significantly improved. Researchers have identified key immune pathways, including tumor necrosis factor (TNF), interleukin-17 (IL-17), and interleukin-23 (IL-23), which play critical roles in disease progression. This deeper insight has paved the way for the development of targeted biologic therapies that offer higher efficacy and improved safety profiles compared to traditional treatments.
The market for treating plaque psoriasis has witnessed remarkable growth in recent years, fueled by advancements in medical research and the development of innovative therapies. Increased awareness among patients and healthcare providers has led to earlier diagnosis and treatment initiation, which contributes to better disease management. Additionally, the rising prevalence of autoimmune disorders ly is a key factor driving the demand for effective therapies.
Healthcare systems across developed and emerging economies are focusing on improving access to dermatological care, further strengthening the growth trajectory of the “Plaque Psoriasis Market Trends“. Digital health tools and teledermatology are also playing a role in expanding reach and enhancing patient engagement.
Plaque Psoriasis Treatment
The most common approaches are topical treatments, which involve applying creams, ointments, or gels directly to the affected areas. These topical medications often contain corticosteroids, retinoids, or vitamin D analogs, which help reduce inflammation and control the excessive skin cell growth associated with psoriasis.
In addition to topical therapies, systemic treatments and phototherapy are widely used, especially in moderate to severe cases. Systemic treatments include oral or injectable medications that target the immune system, while phototherapy involves controlled exposure to ultraviolet light under medical supervision.
Recent advancements have significantly transformed the treatment landscape. Biologic therapies, which specifically target immune pathways such as TNF-alpha, IL-17, and IL-23, have become the cornerstone for managing moderate to severe plaque psoriasis. These therapies offer higher efficacy, longer remission periods, and improved quality of life for patients.
The emergence of biosimilars has also played a crucial role in making advanced treatments more accessible and cost-effective. These alternatives to branded biologics are driving competition and expanding treatment options across markets.
It covers the details of conventional and current medical therapies available in the Plaque Psoriasis market for the treatment of the condition. It also provides Plaque Psoriasis treatment algorithms and guidelines in the United States, Europe, and Japan. These guidelines emphasize personalized treatment approaches based on disease severity, patient comorbidities, and response to prior therapies.
The integration of precision medicine and biomarker-driven therapies is expected to further enhance treatment outcomes. As research continues, the “Plaque Psoriasis Market Growth“ is anticipated to accelerate, supported by a robust pipeline of innovative drugs and combination therapies.
Plaque Psoriasis Epidemiology
The Plaque Psoriasis epidemiology section provides insights about the historical and current Plaque Psoriasis patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
This part of the Plaque Psoriasis market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. Epidemiological studies indicate that plaque psoriasis affects millions of individuals worldwide, with varying prevalence across regions due to genetic, environmental, and lifestyle factors.
Key Findings from the Plaque Psoriasis Epidemiological Analysis
The disease epidemiology covered in the report provides historical as well as forecasted Plaque Psoriasis prevalence scenario in the 7MM covering:
- United States
- EU5 countries (Germany, Spain, Italy, France, and the United Kingdom)
- Japan
The study period spans from 2020 to 2034, highlighting both past trends and future projections. The increasing prevalence of plaque psoriasis is attributed to factors such as rising obesity rates, stress, smoking, and genetic predisposition.
The report also emphasizes the growing diagnosed patient pool, driven by improved healthcare infrastructure and awareness campaigns. Early diagnosis and intervention are becoming more common, which positively impacts treatment outcomes and market demand.
Furthermore, the epidemiology segment explores unmet needs in certain patient populations, including pediatric and elderly patients, who require tailored therapeutic approaches. These insights are crucial for stakeholders aiming to capitalize on opportunities within the “Plaque Psoriasis Market Forecast“.
Plaque Psoriasis Market Recent Breakthroughs and Developments
- In May 2025, Teva Pharmaceuticals and Alvotech announced that the FDA has approved SELARSDI™ (ustekinumab-aekn) injection as interchangeable with the reference biologic Stelara® (ustekinumab). Starting April 30, 2025, SELARSDI is available in all presentations matching the reference product, for the treatment of adults and pediatric patients with psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis.
- In April 2025, Celltrion announced that the FDA designated YUFLYMA® (adalimumab-aaty) as an interchangeable biosimilar to Humira® (adalimumab). YUFLYMA is a high-concentration, citrate-free formulation approved for multiple inflammatory indications.
These developments underscore the growing importance of biosimilars in enhancing treatment accessibility and reducing healthcare costs. Regulatory support and streamlined approval pathways are encouraging more companies to enter the biosimilar space, intensifying competition and fostering innovation.
Key Plaque Psoriasis Companies
The competitive landscape of the Plaque Psoriasis market is characterized by the presence of several and regional players focusing on research, development, and commercialization of advanced therapies. Key companies include:
- Dermavant Sciences GmbH
- IQVIA Biotech
- UCB Biopharma SRL
- Parexel
- Samsung Bioepis Co., Ltd
- Durect
- Astellas
- Biogen
- Dow Pharmaceutical Sciences
- Shire
- Zalicus
- AbbVie
- Santalis Pharmaceuticals Inc
- Maruho Co Ltd
- Novartis
- AstraZeneca
- Pfizer
These companies are actively engaged in strategic collaborations, mergers, acquisitions, and product launches to strengthen their market position. Continuous investment in R&D and expansion into emerging markets are key strategies adopted by leading players.
The increasing focus on biologics, biosimilars, and targeted therapies is expected to reshape the competitive dynamics of the market. Companies are also leveraging digital technologies and real-world evidence to optimize clinical outcomes and enhance patient engagement.
Conclusion
The Plaque Psoriasis market is poised for substantial growth over the coming years, driven by innovation, rising disease prevalence, and expanding treatment options
- Strong pipeline of biologics and biosimilars
- Increasing awareness and diagnosis rates
- Advancements in personalized medicine approaches
- Growing investments in research and development
- Expanding access to healthcare in emerging markets
As the market continues to evolve, stakeholders must focus on innovation, affordability, and patient-centric solutions to address unmet needs and sustain long-term growth.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
